Undoubtedly true. However, Copaxone’s claim to fame has never been stellar efficacy, but rather its modest efficacy and longstanding safety profile. Moreover, it helps Copaxone a little that BG-12 was not shown to be statsig superior on the primary or secondary efficacy endpoints, and hence sales reps will be unable to legally promote BG-12 as superior.
All told, I do not expect the CONFIRM study to have much impact, if any, on Copaxone sales.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.